BioCentury
ARTICLE | Financial News

Ariad reports first Iclusig sales

May 8, 2013 12:19 AM UTC

Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) reported $6.4 million in net sales of leukemia drug Iclusig ponatinib -- Ariad's sole marketed product -- in its first full quarter of availability. The Street was expecting $5 million. FDA granted accelerated approval to Iclusig in December to treat chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) that is resistant to or intolerant of prior treatment with tyrosine kinase inhibitors (TKIs). The pan-BCR-ABL TKI is under accelerated assessment in Europe for the indications, where Ariad said it expects a decision this quarter. EMA's CHMP recommended approval of an MAA for Iclusig in March (see BioCentury Extra, Dec. 14, 2012). ...